Antioxidant Claim Concerns In FDA Warning To Personal Care Ingredient Firm
This article was originally published in The Tan Sheet
Executive Summary
FDA’s letter to Essential Wholesale – one of two drug claim warnings issued to cosmetics firms in November – highlights claims for non-monograph ingredients that render the firm’s offerings drugs, according to the agency. The letter followed an inspection of the company’s facility in April 2014 and a review of its website.
You may also be interested in...
Cell Vitals ‘Revolution’ Quelled? FDA Warns About Stem-Cell Claims
Claims promoting Cell Vitals’ ReLuma skin care line render the products unapproved drugs, FDA says. Marketed as “A Revolution in Stem Cell Skin Care,” the products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the firms says.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.